Zhe Liu

Dr. Zhe Liu


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2023 in Drug Resistance Updates
Verified
Journal Article
Open access
PXPeng Xing
Peng Xing
SWShuo Wang
Shuo Wang
YCYu Cao
Yu Cao
BLBo Liu
Bo Liu
FZFeifei Zheng
Feifei Zheng
ZLZhe Liu
Zhe Liu
Adenocarcinoma is a common type of malignant tumor, originating from glandular epithelial cells in various organs, such as pancreas, breast, lung, stomach, colon, rectus, and prostate. For patients who lose the opportunity for radical surgery, medication is available to provide potential clinical benefits. However, drug resistance is a big obstacle to obtain desired clinical prognosis. In this review, we provide a summary of treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs, including pancreatic cancer, gastric adenocarcinoma, colorectal adenocarcinoma, lung adenocarcinoma, and prostate cancer. Although the underlying molecular mechanisms involved in drug resistance of adenocarcinoma vary from one organ to the other, there are several targets that are universal for drug resistance in adenocarcinoma, and targeting these molecules could potentially reverse drug resistance in the treatment of adenocarcinomas.

6 August 2024 in Drug Resistance Updates
Verified
Journal Article
Closed access
DDDaosong Dong
Daosong Dong
XYXue Yu
Xue Yu
JXJingjing Xu
Jingjing Xu
NYNa Yu
Na Yu
ZLZhe Liu
Zhe Liu
YSYanbin Sun
Yanbin Sun

29 August 2024 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
MGMing Gu
Ming Gu
YLYang Liu
Yang Liu
WZWenhui Zheng
Wenhui Zheng
ZJZuoqian Jing
Zuoqian Jing
XLXiang Li
Xiang Li
WGWei Gao
Wei Gao

2 August 2023 in Cytokine & Growth Factor Reviews
Verified
Journal Article
Closed access
WGWei Guo
Wei Guo
PYPeiyao Ying
Peiyao Ying
RMRuiyang Ma
Ruiyang Ma
ZJZuoqian Jing
Zuoqian Jing
GMGang Ma
Gang Ma
ZLZhe Liu
Zhe Liu

22 June 2024 in Antioxidants
Verified
Journal Article
Open access
PDF file
HZHaomeng Zhang
Haomeng Zhang
YLYong Liu
Yong Liu
KZKe Zhang
Ke Zhang
ZHZhixuan Hong
Zhixuan Hong
ZLZongfeng Liu
Zongfeng Liu
YXYuanhong Xu
Yuanhong Xu
Cancer cells subvert multiple properties of normal cells, including escaping strict cell cycle regulation, gaining resistance to cell death, and remodeling the tumor microenvironment. The hallmarks of cancer have recently been updated and summarized. Nuclear factor erythroid 2-related factor 1 (NFE2L1, also named NRF1) belongs to the cap’n’collar (CNC) basic-region leucine zipper (bZIP) family. It acts as a transcription factor and is indispensable for maintaining both cellular homoeostasis and organ integrity during development and growth, as well as adaptive responses to pathophysiological stressors. In addition, NFE2L1 mediates the proteasome bounce-back effect in the clinical proteasome inhibitor therapy of neuroblastoma, multiple myeloma, and triple-negative breast cancer, which quickly induces proteasome inhibitor resistance. Recent studies have shown that NFE2L1 mediates cell proliferation and metabolic reprogramming in various cancer cell lines. We combined the framework provided by “hallmarks of cancer” with recent research on NFE2L1 to summarize the role and mechanism of NFE2L1 in cancer. These ongoing efforts aim to contribute to the development of potential novel cancer therapies that target the NFE2L1 pathway and its activity.

24 August 2024 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
HLHuina Lv
Huina Lv
YDYang Du
Yang Du
PXPeng Xin
Peng Xin
YZYifan Zhong
Yifan Zhong
ZLZhe Liu
Zhe Liu
YJYuchen Jing
Yuchen Jing